The increasing complexity of cancer chemotherapy makes it mandatory that pharmacists be familiar with these highly toxic agents. This column focuses on the commercially available and investigational agents used to treat malignant diseases and reviews issues related to the preparation, dispensing, and administration of cancer chemotherapy.
Get full access to this article
View all access options for this article.
References
1.
National Comprehensive Cancer Network.NCCN testicular cancer practice guidelines. The Complete Library of NCCN Oncology Practice Guidelines [CD-ROM]. Rockledge, PA: National Comprehensive Cancer Network; 2003.
2.
HintonS., CatalanoP.J., EinhornL.H.Cisplatin, etoposide and either bleomycin or ifosfamide in the treatment of disseminated germ cell tumors. Cancer.2003; 97: 1869–75.
3.
NicholsC.R., CatalanoP.J., CrawfordE.D.Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: An Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B study. J Clin Oncol.1998; 16: 1287–93.
4.
LoehrerPJSr, GoninR., NicholsC.R.Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor. J Clin Oncol.1998; 16: 2500–4.
5.
LoehrerPJSr, LauerR., RothB.J.Salvage therapy in recurrent germ cell cancer: Ifosfamide and cisplatin plus either vinblastine or etoposide. Ann Intern Med.1988; 109: 540–6.
6.
McCaffreyJ.A., MazumdarM., BajorinD.F.Ifosfamide- and cisplatin-containing chemotherapy as first-line salvage therapy in germ cell tumors: Response and survival. J Clin Oncol.1997; 15: 2559–63.
7.
FarhatF., CulineS., TheodoreC.Cisplatin and ifosfamide with either vinblastine or etoposide as salvage therapy for refractory or relapsing germ cell tumor patients: The Institut Gustave Roussy experience. Cancer.1996; 77: 1193–7.
8.
ClemmC., HartensteinR., WillichN.Combination chemotherapy with vinblastine, ifosfamide and cisplatin in bulky seminoma. Acta Oncol.1989; 28: 231–5.
9.
ClemmC., HartensteinR., WillichN.Vinblastine-ifosfamide-cisplatin treatment of bulky seminoma. Cancer.1986; 58: 2203–7.
10.
HarstrickA., SchmollH., WilkeH.Cisplatin, etoposide, and ifosfamide salvage therapy for refractory or relapsing germ cell carcinoma. J Clin Oncol.1991; 9: 1549–55.
11.
PizzocaroG., SalvioniR., PivaL.Modified cisplatin, etoposide (or vinblastine) and ifosfamide salvage therapy for male germ-cell tumors. Long-term results. Ann Oncol.1992; 3: 21–16.
12.
HeskethP.J., KrisM.G., GrunbergS.M.Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol.1997; 15: 103–9.
13.
American Society of Health-System Pharmacists.ASHP therapeutic guidelines on the pharmacologic management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or radiation therapy or undergoing surgery. Am J Health Syst Pharm.1999; 56: 729–64.
14.
NCCN antiemesis practice guidelines.The Complete Library of NCCN Oncology Practice Guidelines (CD-ROM). Rockledge, PA: National Comprehensive Cancer Network; 2003.
15.
GrallaR.J., OsobaD., KrisM.G.Recommendations for the use of antiemetics: Evidence-based, clinical practice guidelines. J Clin Oncol.1999; 17: 2971–94.
16.
CornelisonT.L., ReedE.Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin. Gynecol Oncol.1993; 50: 147–58.
17.
KintzelP.E., DorrR.T.Anticancer drug renal toxicity and elimination: Dosing guidelines for altered renal function. Cancer Treat Rev.1995; 21: 33–64.
OzerH., ArmitageJ.O., BennettC.L.2000 update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines. J Clin Oncol.2000; 18: 3558–85.
LymanG.H., KudererN., GreeneJ.The economics of febrile neutropenia: Implications for the use of colony-stimulating factors. Eur J Cancer.1998; 34: 1857–64.
22.
LymanG.H., BalducciL.Update of the economic analyses of the use of colony-stimulating factors. Curr Opin Hematol.1999; 6: 145–51.
23.
LarsonD.L.Treatment of tissue extravasation by antitumor agents. Cancer.1982; 49: 1796–9.
24.
LarsonD.L.What is the appropriate management of tissue extravasation by antitumor agents?Plast Reconstr Surg.1985; 75: 397–402.
25.
MullinS., BeckwithM.C., TylerL.S.Prevention and management of antineoplastic extravasation injury. Hosp Pharm.2000; 35: 57–74.
26.
SiuL.L., MooreM.J.Use of mesna to prevent ifosfamide-induced urotoxicity. Support Care Cancer.1998; 6: 144–54.
27.
PattersonW.P., ReamsG.P.Renal and electrolyte abnormalities due to chemotherapy. In: The Chemotherapy Sourcebook.3rd ed.PerryM.C., ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2001, 494–504.
28.
KintzelP.E., DorrR.T.Anticancer drug renal toxicity and elimination: Dosing guidelines for altered renal function. Cancer Treat Rev.1995; 21: 33–64.
29.
KingP.D., PerryM.C.Hepatotoxicity of chemotherapeutic and oncologic agents. Gastroenterol Clin North Am.1995; 24: 969–89.
30.
KingP.D., PerryM.C.Hepatotoxicity of chemotherapeutic agents. In: The Chemotherapy Sourcebook.3rd ed.PerryM.C., ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2001, 483–93.
